NLST中CT检出的微结节:患病率及其与阳性筛查和肺癌的关系
该研究基于NLST中26,722名接受低剂量CT筛查的参与者,评估微结节(4mm结节且无其他发现)的患病率及恶性潜能。42%的参与者至少有一次CT显示微结节,其中13例微结节最终发展为肺癌,但年度CT随访不影响总生存。
要点
- 微结节在肺癌筛查人群中常见,42%的参与者至少有一次CT显示微结节。
- 微结节可发展为肺癌,但仅占CT组肺癌的1.2%,年度CT随访是适当的。
- 微结节发展为肺癌的患者总生存与CT组其他非小细胞肺癌患者无显著差异(p=0.36)。
核心结论
- 微结节在肺癌筛查参与者中常见且可发展为肺癌,但年度CT随访监测是适当的,不影响总生存或结局。
研究设计与样本
- 基于国家肺癌筛查试验(NLST)的回顾性分析,共26,722名参与者接受低剂量CT筛查。
- 从NLST数据库中选取有微结节记录且发展为肺癌的参与者,由经验丰富的胸部放射科医生复习CT图像。
主要发现
- 11,326(42%)名参与者至少有一次CT显示微结节。
- 5,560(49%)名微结节参与者至少有一次阳性CT,其中409(3.6%)例随后诊断为肺癌。
- 409例肺癌中,13例微结节发展为肺癌,占CT组肺癌的1.2%(13/1089),占所有微结节病例的0.11%(13/11,326)。
- 微结节基线平均大小为3.0×2.5 mm,阳性CT时平均大小为11.1×8.6 mm,平均变化8.1×6.1 mm。
- 从首次CT显示微结节到阳性CT平均459天,到肺癌诊断平均617天,从阳性CT到肺癌诊断平均160天。
关键数值与推荐
- 微结节定义为4mm结节且无其他发现,在NLST中归类为阴性检查。
- 13例肺癌中,组织学为1例小细胞癌和12例非小细胞癌,分期IA 8例(62%)、IB 2例(15%)、IIIA、IIIB和IV各1例。
临床怎么用
- 对于筛查中发现的微结节,年度CT随访监测是适当的,无需额外干预。
- 微结节随访不影响总生存,临床可按照常规筛查流程管理。
局限性
- 本研究为回顾性分析,可能存在选择偏倚。
- 微结节发展为肺癌的病例数较少(13例),统计效力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the National Lung Screening Trial (NLST) all cases with a 4-mm nodule (micronodule) and no other findings were classified as a negative study. The prevalence and malignant potential of micronodules in the NLST is evaluated to understand if this classification was appropriate. METHODS AND MATERIALS: In the NLST a total of 53,452 participants were enrolled with 26,722 undergoing low-dose computed tomography (CT) screening. To determine whether a micronodule developed into a lung cancer, a list from the NLST database of those participants who developed lung cancer and had a micronodule recorded was selected. The CT images of this subset were reviewed by experienced, fellowship-trained thoracic radiologists (R.F.M., C.C., P.M.B., and D.R.A.), all of whom participated as readers in the NLST. RESULTS: There were 26,722 participants who underwent CT in the NLST, of which 11,326 (42%) participants had at least one CT with a micronodule. Five thousand five hundred sixty (49%) of these participants had at least one positive CT examination, of which 409 (3.6%) subsequently were diagnosed with lung cancer. Of the 409 lung cancer cases with a micronodule recorded, there were 13 cases in which a micronodule developed into lung cancer. Considering the 13 cases, they represent 1.2% (13 of 1089) of the lung cancers diagnosed in the CT arm of the NLST and 0.11% (13 of 11,326) of the total micronodule cases. Additionally they represent 0.23% (13 of 5560) of the micronodule and at least one positive CT examination cases and 3.2% (13 of 409) of the micronodule cases diagnosed with lung cancer. The average size of the nodule at baseline (recorded as maximum diameter by perpendicular diameter) was 3.0 × 2.5 mm (ranges 2 x 4 mm and 2 x 4 mm) and at the positive CT the nodule was 11.1 × 8.6 mm (ranges, 6 x 20 mm and 5 x 14 mm); a difference of average change in size of 8.1 × 6.1 mm. The average number of days from first CT with a micronodule recorded to positive CT was 459 days (range, 338 - 723 days), the mean time from first CT with micronodule to lung cancer diagnosis was 617 days (range, 380 - 1140 days) and the mean time from positive CT to lung cancer diagnosis was 160 days (range, 18 - 417 days). Histologically, there was one small cell carcinoma and 12 non-small cell with stages of IA in 8 (62%), stage IB in 2 (15%), and 1 each stage IIIA, IIIB, and IV. The overall survival of NSCLC cases with a micronodule was not significantly different than the survival of the CT subset diagnosed with NSCL (p = 0.36). CONCLUSIONS: Micronodules are common among lung cancer-screened participants and are capable of developing into lung cancer; however, following micronodules by annual CT screening surveillance is appropriate and does not impact overall survival or outcome.
引用
- Munden RF, Chiles C, Boiselle PM, et al. Micronodules Detected on Computed Tomography During the National Lung Screening Trial: Prevalence and Relation to Positive Studies and Lung Cancer. J Thorac Oncol. 2019. PMID: 31295576. doi:10.1016/j.jtho.2019.05.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。